Antihypertensive ACEIs associated with reduced cardiovascular events, death

The blood pressure medication angiotensin-converting enzyme inhibitors (ACEIs) appear to reduce major cardiovascular events and death, as well death from all other causes, in patients with diabetes, while angiotensin II receptor blockers (ARBs) appear to have no such effect on those outcomes.

Approximately 285 million adults worldwide have diabetes, and diabetes is a risk factor for cardiovascular diseases (CV). The American Diabetes Association recommends that patients with diabetes and high be treated with an ACEI or an ARB.

The authors examined the available medical literature to conduct a meta-analysis that examined the effects of ACEIs and ARBs on major CV events and death, as well as death from all other causes. The authors identified 35 clinical trials: 23 compared ACEIs with placebo or other active drugs (n=32,827 patients) and 13 other trials compared ARBs with no therapy (controls) (n=23,867 patients).

An analysis of the suggests that ACEIs reduce the risk of death from all causes by 13 percent, cut the risk CV deaths by 17 percent and lower the risk of major CV events by 14 percent, including myocardial infarction (heart attack) by 21 percent and heart failure by 19 percent. ARBS did not affect all-cause mortality, CV death rate and major CV events, with the exception of . ACEIs and ARBs were not associated with a decreased risk for stroke in patients with diabetes.

"Our meta-analysis shows that ACEIs reduce all-cause mortality, CV mortality and major CV events in patients with DM [diabetes mellitus], whereas ARBs have no beneficial effects on these outcomes. Thus, ACEIs should be considered as first-line therapy to limit the excess mortality and morbidity in this population," Jun Cheng, M.D., of the Medical School of Zhejiang University, China, and colleagues wrote in their JAMA Internal Medicine paper.

More information: JAMA Intern Med. Published online March 31, 2014. DOI: 10.1001/jamainternmed.2014.348

Related Stories

Many psoriasis patients undertreated for CV risk factors

date Jun 22, 2012

(HealthDay) -- A large proportion of patients with moderate-to-severe plaque psoriasis are underdiagnosed and undertreated for cardiovascular (CV) risk factors, according to a study published in the July issue ...

Recommended for you

Catheterization increasing for seniors with STEMI

date 14 hours ago

(HealthDay)—From 1999 to 2009 there was a decrease in the proportion of older adults with ST-segment elevation acute myocardial infarction (STEMI) who did not undergo cardiac catheterization, according ...

Race influences warfarin dose, study says

date 22 hours ago

A new report demonstrates that clinical and genetic factors affecting dose requirements for warfarin vary by race. The study, published online today in Blood, the Journal of the American Society of Hematology (ASH), propose ...

Even moderate BMI reduction could ease A-fib burden

date May 29, 2015

(HealthDay)—Incremental increases in body mass index (BMI) are associated with excess risk of incident, postoperative, and post-ablation atrial fibrillation (AF), according to a review published online ...

Personalized saline may provide solution to heart death

date May 29, 2015

Saline solution is a staple of every hospital. No matter the ailment, doctors have known for more than a century that saline is key to keeping patients hydrated and maintaining their blood pressure levels. ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.